Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan +/- bevacizumab vs SOC in platinum-sensitive recurrent ovarian cancer
NCT06824467Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants With One or More Adverse Events (AEs) at 6 weeks, Number of Participants Who Discontinue Study Intervention Due to an AE at 6 weeks and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06824467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824467.